Office of Research
Clinical Trials

Studying throat growths in adults to help find better treatments

This study looks at growths in the voice box and airway caused by a virus. When adults have planned procedures to treat these growths, a small amount of tissue (and sometimes blood) is collected and used to grow cells in the lab. Researchers study the virus and genes and test different medicines on the lab grown cells to see what works best. There are no extra study visits. Participation continues while a person receives usual care. The main risk is a privacy breach, and steps are taken to protect information. Results are not shared with participants. About 50 adults are expected to take part.

TAPUR Study: FDA Approved Drugs Targeting Tumor Gene Abnormalities

The TAPUR Study is focused on understanding how FDA-approved drugs that target specific abnormalities in tumor genes work for patients with advanced cancers. These include solid tumors, multiple myeloma, and non-Hodgkin lymphoma that have a detectable genetic feature that can potentially be treated with these medicines. The study evaluates participants' responses, safety of treatments, survival rates, and helps to form ideas for new clinical trials based on real-world usage of these therapies. Anyone aged 12 or older with certain advanced cancers whose condition can be measured and who meets other criteria may participate. However, those with certain conditions like primary brain tumors or unmeasurable disease may not be eligible.

This study may be appropriate for those with: Relapsed / Refractory Cancer

A Study of LP-118 in Patients With Advanced Tumors

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects. The study has a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b). Secondary objectives of the study are to evaluate preliminary efficacy regarding the effect of LP-118 on objective response rate (ORR) using disease specific response criteria, progression-free survival (PFS), and duration of response (DOR), and overall survival (OS) in adult subjects with relapsed/refractory blood cancers.

This study may be appropriate for those with: Relapsed / Refractory Cancer